Value of Serum miR-23a, miR-30d, and miR-146a Biomarkers in ST-Elevation Myocardial Infarction

Tomas Bukauskas
Rytis Mickus
Darius Cereskevicius
Andrius Macas

Background: The aim of this study was to analyze the relative expression level of miR-30d-5p, miR-23a-3p, and miR-146a-5p, and to comprehensively assess the diagnostic and predictive possibilities of these miRNAs. Their expression changes have not yet been sufficiently investigated during acute myocardial infarction. Therefore, it is important to comprehensively assess the diagnostic and predictive possibilities of these micro-ribonucleic acids (miRNAs).

Material/Methods: Random patients with ST-elevated myocardial infarction (STEMI) were enrolled into the study group. The control group was comprised of patients with no inflammation or ischemic heart disease who were hospitalized for minor elective surgery. The relative expression level for each miRNA was determined by reverse transcription quantitative polymerase chain reaction (RT-qPCR)-analysis.

Results: There were 88 participants enrolled into the study: 62 patients were diagnosed with STEMI and there were 26 healthy controls. Expressions of miR-30d-5p, miR-146a-5p, and miR-23a-3p were respectively 1.581-fold, 4.048-fold, and 4.857-fold lower in patients with STEMI compared to the control group patients (all P values were <0.001). Downregulation of miR-23a-3p was significantly negatively correlated with risk scores of GRACE (Global Registry of Acute Coronary Events) and APACHE II (Acute Physiology and Chronic Health Evaluation II). MiR-23a-3p was a fair predictor for STEMI: area under the curve (AUC)=0.806. Cox regression analysis revealed that expression levels of analyzed miRNAs were not significantly associated with negative endpoints at 1 month after the onset of STEMI.

Conclusions: All investigated miRNAs were differentially expressed when comparing patients with STEMI and control group individuals. The evaluation of miR-23a-3p expression levels in serum could be useful to assess the severity of STEMI and as a potential diagnostic biomarker of this condition. In addition, miR-23a-3p may provide limited short-term prognostic value for STEMI patients.

MeSH Keywords: Biological Markers • MicroRNAs • Myocardial Infarction

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/913743
Background

Micro-ribonucleic acids (miRNAs) are small non-coding transcripts. They play an important role in transcriptional activity of a cell, managing differentiation, metabolism, development, interaction and other processes. Some potential diagnostic, prognostic and predictive roles of miRNAs have already been described [1,2]. Nowadays, miRNAs are being widely explored as disease biomarkers.

MiRNAs have an important role in regulation of cardiovascular disease pathophysiology [3]. They are involved in the acute inflammatory process and systemic response to ischemic cardiac injury [4]. They are associated with myocardial ischemia-reperfusion injury and also associated with myocardial cell apoptosis [5]. Therefore, circulating miRNAs may have a potential as biomarkers of acute myocardial infarction (AMI) [6].

It has been established that miR-30d could be involved in systemic inflammatory response, and neovascularization processes after AMI [7]. A previous study reported miR-23a as a possible biomarker for coronary artery disease (CAD) [8]. It has been confirmed that miR-23a is related to myocardial hypertrophy [9]. Altered expression levels of miR-30d and miR-23a may be useful to identify non-infective systemic inflammatory response (SIR) processes, such as AMI [10]. The expression level change of stress related miR-146a was found to potentially attenuate cardiac dysfunction and apoptosis during AMI in mice [11].

As aforementioned, evidence has demonstrated that miR-30d-5p, miR-23a-3p, and miR-146a-5 could be involved in cardiovascular events. However, their expression level changes have not yet been sufficiently investigated during AMI. Most of the previous data on these miRNAs have been obtained from animal studies and there is little evidence of their value and clinical implication in humans. We decided to analyze expression levels of circulating serum miR-30d-5p, miR-23a-3p, and miR-146a-5 and to comprehensively assess the diagnostic and predictive possibilities of these miRNAs for patients with ST-elevated myocardial infarction (STEMI).

Material and Methods

Ethics statement

The current monocentric, prospective study was approved by the Kaunas Regional Biomedical Research Ethics Committee (No. BE-2-19) and the study was carried out in accordance with the approved guidelines. All data were anonymized. Patients meeting the inclusion criteria were interviewed after hospitalization. The study purposes and benefits were explained. The informed consent form was approved by the Regional Ethics Committee, together with the description of the study, which was provided to the patient with sufficient time for potential participants to read the informed consent document, and ask questions prior to signing. Written informed consent was obtained from each individual.

Study population

Random patients with STEMI, who were admitted to a cardiac intensive care unit (CICU) and underwent emergency percutaneous coronary intervention (PCI) were enrolled into the study group. The control group was comprised of patients with no inflammation or ischemic heart disease who were hospitalized for minor elective surgery at Lithuanian University of Health Sciences between July 2018 and October 2018. Acute coronary syndrome (ACS), AMI, and STEMI were diagnosed according to international standards [12] by independent, experienced CICU physicians who were unaware of the miRNAs data. Patients were provided with treatment for STEMI, according to recent guidelines [13].

Data, describing demographics and severity of illness were gathered for each study participant. This included Killip class, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, Global Registry of Acute Coronary Events (GRACE) scores, comorbidities and routine clinical blood test results. All participants underwent clinical evaluation, including physical examination and 12-lead electrocardiography.

Patients were excluded from the study if any of the following components presented: refusal to participate in the study at any stage, oncological disease, pregnancy, refusal to participate, convicts, patients under 18 years old, acute cerebrovascular disease, or coronary arteries free of significant lesions detected by PCI. Endpoints or events were determined by reviewing the medical records and by follow-up for up to 1 month. Primary outcome was the expression levels of circulating serum miR-30d-5p, miR-23a-3p, and miR-146a-5 in patients with STEMI and in healthy patients. Secondary outcomes were diagnostic and predictive possibilities of these miRNAs.

Blood sampling and data collection

Blood samples from patients with STEMI were collected simultaneously to other standard-care assessments to minimize/eliminate the need for additional punctures in the first 24 hours of CICU admission. Samples from the control group patients were drawn through venous puncture prior to surgical intervention. Collected blood specimens were stored in tubes containing clot activator and were left at room temperature (15–25°C) from 10 minutes to 1 hour for complete clotting. Tubes were centrifuged at 3000 rpm for 10 minutes at 4°C, using a swinging bucket rotor. Afterwards, the resulting
serum samples were transferred into new RNase/DNase-free Eppendorf tubes. Hemolysis in serum samples was measured using the QIAxpert spectrophotometer (Qiagen GmbH). We measured oxyhemoglobin absorbance at k = 414 nm [14]. The value of ≤0.2 absorption units (AU) was used as the threshold for samples inclusion [15]. Samples were stored at ~80°C until further RNA purification, according to the protocol of manufacturer.

RNA extraction

The miRNeasy Serum/Plasma Kit (Cat No. 217184 Qiagen GmbH) was used to purify cell-free total RNA from human serum following the instructions of the manufacturer. In order to monitor miRNA purification and amplification, the corresponding Caenorhabditis elegans miR-39 (miRNeasy Serum/Plasma Spike-In Control, Cat No. 219610 Qiagen GmbH) was added after sample lysis. RNAs were eluted in 14 μL of RNase-free water.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

The miScript PCR System (Qiagen GmbH) was used for the specific detection and relative quantification of microRNAs according to the manufacturer’s protocol. Total RNA (1.5 μL) was reverse transcribed using the Reverse Transcription Kit (miScript II RT Kit Cat No. 218161 Qiagen GmbH). In the reverse transcription (RT) with miScript HiSpec Buffer, mature miRNAs were polyadenylated by poly(A) polymerase and reverse transcribed into complementary DNA (cDNA) with oligo-dT priming. cDNA samples were diluted in 200 μL of nucleic free water and were stored at ~20°C until qPCR. Next, 2.0 μL of the diluted cDNA samples were used as a template for qPCR reactions using miScript Primer Assays (Qiagen GmbH) for miR-23a-3p, miR-30d-5p, and miR-146a-5p in combination with the miScript SYBR Green PCR Kit (Cat No. 218073 Qiagen GmbH), which contains the miScript Universal Primer (reverse primer). The combination of polyadenylation and the universal tag addition ensured that miScript Primer Assays do not detect genomic DNA. Rotor Gene Q real-time PCR cycler (Qiagen GmbH) was used for qPCR. Cel-miR-39-3p was used for normalization. The Ct value was defined as the number of PCR cycles required for the fluorescence signal to exceed the detection threshold value [16]. The relative expression level for each miRNA was calculated using the 2−ΔΔCt method. Ct values below 36 were included.

Statistical analysis

Normal distribution data were expressed as mean ± standard deviation (SD). The normality of data was assessed with the Kolmogorov-Smirnov or Shapiro Wilks tests. Groups were compared by independent samples t-test or one-way analysis of variance (ANOVA) for comparison between multiple groups. Non-normal distribution data were expressed as median (min, max) or median and interquartile range. For non-parametric statistics, Mann-Whitney U test or Kruskal-Wallis ANOVA were performed for comparison between groups. The difference in frequency distribution between groups was determined by chi-square test. Linear regression analysis was performed to determine correlations. Fold differences were calculated for the miRNA expression values in patients with STEMI compared with healthy controls. The 1-month survival was calculated by Kaplan-Meier curves with log-rank test. A P value <0.05 was considered statistically significant. The ability to distinguish STEMI group and control group was characterized by the receiver operating characteristic (ROC) curve. The sample size of at least 18 patients was determined based on previous studies during the analysis of all 3 miRNAs for assessing diagnostic value. The statistical analysis was performed using IBM SPSS Statistics software (v. 23.0 Chicago, IL, USA). Statistical tests were 2-sided with P<0.05 considered significant.

Results

Baseline characteristics

There were 113 potential candidates who were initially included in our study analysis, however 25 patients were excluded due to a mismatch of the inclusion criteria, refusal to participate, or hemolysis in samples (Figure 1). Finally, 88 participants were enrolled into the study: 62 patients were diagnosed with STEMI and there were 26 healthy controls. The 1-month survival was calculated by Kaplan-Meier curves with log-rank test. A P value <0.05 was considered statistically significant. The ability to distinguish STEMI group and control group was characterized by the receiver operating characteristic (ROC) curve. The sample size of at least 18 patients was determined based on previous studies during the analysis of all 3 miRNAs for assessing diagnostic value. The statistical analysis was performed using IBM SPSS Statistics software (v. 23.0 Chicago, IL, USA). Statistical tests were 2-sided with P<0.05 considered significant.

Figure 1. Study design. STEMI, ST-segment elevation myocardial infarction.
|                                      | STEMI (n=62) | HP (n=26) | P      |
|--------------------------------------|-------------|-----------|--------|
| Gender, male (n, %)                  | 46 (74.2)   | 20 (76.9) | 0.791  |
| Age (years)*                         | 64 (12)     | 42 (13)   | <0.001 |
| Smoking (n, %)                       | 29 (46.8)   | 2 (7.7)   | 0.001  |
| Body mass index (kg/m²)*             | 29 (6)      | 28 (6)    | 0.331  |
| Diabetes (n, %)                      | 15 (24.2)   | 2 (7.7)   | 0.084  |
| Hypertension (n, %)                  | 43 (69.4)   | 2 (7.7)   | <0.001 |
| Arrhythmia (n, %)                    | 14 (22.6)   | 0         |        |
| Ischemic heart disease (n, %)        | 28 (45.2)   | 0         |        |
| SBP (mmHg)*                          | 134 (29)    | 140 (10)  | 0.383  |
| DBP (mmHg)*                          | 78 (19)     | 82 (14)   | 0.133  |
| MBP (mmHg)*                          | 97 (21)     | 101 (12)  | 0.371  |
| Heart rate (t/min)*                  | 75 (22)     | 78 (10)   | 0.562  |
| Chronic kidney disease (n, %)        | 2 (3.2)     | 0         |        |
| Acute kidney failure (n, %)          | 16 (25.8)   | 0         |        |
| eGFR (mL/min/1.73 m²)*               | 68 (28)     | 122 (13)  | <0.001 |
| Chronic obstructive pulmonary disease (n, %) | 1 (1.6)  | 0         |        |
| Medicines (n, %)                     | 37 (59.7)   | 2 (7.7)   | 0.001  |
| Allergy (n, %)                       | 3 (4.8)     | 0         |        |
| Glu (mmol/L)                         | 7.7 (4.7; 36.5) | 5.6 (5; 7.0) | <0.001 |
| CREA (µmol/L)                        | 93 (51; 721) | 76 (48; 118) | 0.01   |
| UREA (mmol/L)                        | 5.9 (3.8; 26.4) | 4.9 (3.0; 6.6) | 0.047  |
| cTnl (ng/mL)                         | 7.1 (0.01; 139) |        |        |
| CRP (mg/L)                           | 4.0 (0.0; 175) | 5.0 (2.0; 8.0) | 0.984  |
| Hb (g/dL)*                           | 13.8 (16.2) | 14 (15.2) | 0.47   |
| RDW (%)                              | 13.8 (12.0; 19.0) | 12.6 (12.0; 13.6) | 0.002  |
| HCT (%)*                             | 41.5 (40)   | 41.8 (41) | 0.775  |
| PLT (×10⁹/L)                         | 205 (95; 482) | 238 (177; 398) | 0.034  |
| WBC (×10⁹/L)                         | 10.8 (4.6; 21.1) | 6.0 (3.5; 10.5) | 0.000  |
| K⁺ (mmol/L)                          | 4.1 (3.0; 5.8) | 4.4 (4.0; 4.9) | 0.000  |
| Na⁺ (mmol/L)                         | 138 (124; 148) | 141 (136; 143) | 0.004  |
| INR                                  | 1.1 (0.9; 1.7) | 1 (0.9; 1.1) | 0.06   |
| APACHE II score                      | 7.5 (1; 33)  | 2 (0; 4)  | 0.000  |
| GRACE score*                         | 12.7 (34)   |          | 0.47   |
| KILLIP class                         | 2 (1; 4)    |          |        |

Data are presented as the median (min, max) or proportion, as appropriate. * Data was normally distributed for these variables, they are presented mean ± standard deviation. STEMI – ST-elevated myocardial infarction; HP – healthy patients; SBP – systolic blood pressure; DBP – diastolic blood pressure; MBP – mean blood pressure; Glu – glucose; CREA – creatinine; eGFR – estimated glomerular filtration rate; cTnl – cardiac troponin I; CRP – C-reactive protein; Hb – hemoglobin; HCT – hematocrit; PLT – platelets; WBC – white blood cells; K⁺ – potassium; Na⁺ – sodium; INR – international normalized ratio; APACHE II score – Acute Physiology And Chronic Health Evaluation II; GRACE score – Global Registry of Acute Coronary Events.
levels, in comparison to the control group individuals. Blood samples were taken 22±6 hours after the onset of symptoms.

Expression levels of miRNAs in the serum

All investigated miRNAs had differing expression levels between the 2 groups. As shown in Figure 2, the expression levels of miR-30d-5p, miR-146a-5p, and miR-23a-3p were respectively 1.581-fold, 4.048-fold, and 4.857-fold lower in patients with STEMI compared to control group patients (all P values were <0.001).

Diagnostic values of miR-30d-5p, miR-146a-5p, and miR-23a-3p

Receiver operating characteristic (ROC) analysis was performed on study and control group patients to assess the diagnostic value of miRNAs (Figure 3). The analysis showed that miR-23a-3p (area under the curve [AUC]=0.806 (95% CI 0.694–0.917); miR-146a-5p AUC 0.800 (95% CI 0.685–0.915); miR-30d-5p AUC 0.745 (95% CI 0.620–0.870). MiRNAs – microRNAs; STEMI – ST-elevated myocardial infarction, AUC – area under the curve.

Correlation of expression values with mortality risk and disease severity

MiRNA expression values were correlated to mortality risk scores of GRACE and APACHE II (Figure 4). MiRNAs expression levels of the patients with high severity of disease and mortality risk were compared with expression levels of non-severe patients. Only expression levels of miR-23a-3p were 3.772-fold lower in patients with GRACE risk score >110 points (probability of in-hospital mortality >1.1%) and 3.274-fold lower in patients with APACHE II morbidity score >10 points (probability of in-hospital mortality >9%) comparing to non-severe STEMI patients; suggesting that a downregulation of circulating miR-23a-3p level may be associated with increased severity of STEMI and a higher risk of death.

Prognostic value of miR-30d-5, miR-146a-5p, and miR-23a-3p

Kaplan-Meier survival analysis was performed to investigate prognostic value. We divided patients into positive (>threshold value) and negative (<threshold value) groups. Threshold values were established from the ROC curves to be –1.829, –1.28, and –0.26 for miR-23a-3p, miR-30d-5p, and miR-146a-5p groups respectively. The sample size analysis showed that at least 12 individuals should be involved in miR-23-3p negative group and 40 patients in miR-23-3p positive group. The survival plot of the Kaplan-Meier curve predicted the miR-23a-3p-negative group (n=21) to have a lower cumulative survival rate than the positive group (n=41) at 1 month after STEMI (P=0.045, Figure 5), but there were no significant differences for miR-30d-5p and miR-146a-5p groups. Cox regression analysis revealed that expression levels of analyzed miRNAs were not significantly associated with negative endpoints at 1 month after the onset of STEMI.
Expressions of miRNAs in STEMI patients with the acute kidney impairment

Estimated glomerular filtration rate (eGFR) was decreased (<60 mL/min/1.73 m²) for 16 patients (25.8%) with STEMI. The role of kidney dysfunction in miRNAs expression levels was analyzed by comparing miRNAs between STEMI patients, with and without the acute kidney impairment, revealing no statistical significance of the miRNA expression ($P>0.05$).

Correlation of expression values with pro-inflammatory mediators

Afterwards, the interdependence of miRNAs to plasma levels of pro-inflammatory mediators (CRP, LEU) was analyzed, but no correlation was found.

Discussion

Serum levels of all investigated miRNAs were lower in STEMI patients compared to control group individuals. The difference in the expression level of miR-30d-5p was the lowest among the groups. Moreover, the diagnostic value of this miRNA was poorer compared to other miRNAs we investigated. MiR-146a-5p showed great STEMI diagnostic value, but did not correlate with mortality risk or severity-of-disease. This study found an impressive decreased level of miR-23a-3p in patients with STEMI compared with healthy patients during the first 24 hours after occurrence of myocardial injury. This finding is supported by previous investigations demonstrating miRNAs involvement in ACS processes [17–20]. Severe disease patients had significantly lower expression levels of miR-23a-3p compared to non-severe disease patients. This negatively correlated with the mortality risk scoring systems. MiR-23a-3p had a fair diagnostic value for STEMI.

Other studies have shown reduced levels of miR-23a in cases of heart injury [17,20]. A significant downregulation of miR-23a and miR-30a was reported by Han et al. in mice models with artificially induced atherosclerotic artery damage and in human patients with CAD in comparison to healthy controls, respectively [20]. Expression of miRNAs could be dependent on time following the onset of STEMI. The report by Wang et al. stated that plasma miR-23a expression level peaks at first 4 hours after the onset of acute MI and gradually returns to control levels over the next 3 days, exhibiting the same trend as cardiac troponin I (cTnI) [8]. Kegang et al. found that expression levels of miR-125-5p and miR-30d-5p were higher in patients with ACS at the very early stage of AMI and started to decrease after 9 hours from the onset [7]. A constant 24-hour long decline of miR-23a expression was detected after the onset of ischemia-reperfusion injury in a rat model [21]. In our study, blood samples were drawn 22±6 hours after the onset of STEMI symptoms. Keeping in mind that the response
of miRNAs expression to treatment is rapid; this could be the reason why our results differed from some other studies where blood samples were collected at earlier phases of AMI. It should be mentioned that expression levels of downregulated miRNAs during early period of ACS gradually increase towards their baseline values after 3 months [22]. Moreover, circulating miRNAs could be differentially expressed in the serum and plasma of the same individual. Therefore, caution must be taken when comparing miRNAs data of various studies, where different obtainment sources are used to generate patterns of miRNAs expression levels in patients with AMI [21].

MI could be characterized as a local decrease of blood flow of the heart following a development of acute ischemia that leads to myocardial injury or necrosis [23]. Heart damage caused by MI depends on duration of ischemia and intensity of subsequent alterations due to reperfusion. Changes of miRNAs expression through different MI phases remain quite unexamined. In addition to necrosis, apoptosis also plays a role in tissue damage after MI, therefore, has pathological and therapeutic implications [12]. Studies show that apoptosis occurs after constant ischemia [24,25]. Therefore, it has been suggested that apoptosis is a major determinant of the infarct size [25]. Findings indicate that the role of miR-23a in cardiomyocyte apoptosis is controversial. For example, one study, using a rat model, revealed that the knockdown of miR-23a by tail injection of chemically modified antisense oligonucleotides (antagomiR) attenuated the ischemic/reperfusion injury and cardiomyocyte apoptosis, indicating that inhibition of miR-23a may have a protective effect [17]. Moreover, Leng et al. showed that inhibition of miR-23a attenuated the downregulation of the antioxidant enzyme manganese superoxide dismutase (MnSOD) and cardiomyocyte apoptosis [26]. It could be hypothesized that the downregulation of miR-23a expression during the early phase of MI may be as a natural protective mechanism. On the other hand, another rat model study showed that the apoptosis rate of myocardial cell increased, while miR-23a expression was downregulated, indicating the protective role of miR-23a in myocardial cell apoptosis [21]. What is more, miR-23a could have an influence on the activity of NF-kB, as well as on NF-kB target genes that encode pro-inflammatory mediators, for example IL-6 and TNF-α [27].

Using a tumor necrosis factor (TNF-α)-induced bone marrow mesenchymal stem cells (BM)-MSC injury model in vitro and a rat MI model in vivo, Mao et al. showed that miR-23a was involved in TNF-α-induced BM-MSC apoptosis through regulating caspase-7 and that the injection of BM-MSCs over-expressing miR-23a could improve left ventricular (LV) function and reduce infarct size in the rat MI model [28].

In our study, ROC analysis presented the high sensitivity and specificity of analyzed miRNAs, especially miR-23-3p (AUC 0.806). This may provide diagnostic information for patients with STEMI in the first 24 hours after the onset of symptoms. Surprisingly, the diagnostic value of miR-23a-3p and miR-146a-5p were shown in one study to be only slightly lower than the high sensitive of cTnI (AUC 0.88; 95% CI 0.86–0.94) [29], which is currently the preferred biomarker for the diagnosis of AMI. So far, little data is known about prognostic value of miR-23a-3p, miR-30d-5p, and miR-146a-5p in patients with STEMI. Jia et al. revealed no correlation of plasma miR-30d-5p expression and adverse cardiac outcomes at 1, 6, and 12 months after the onset of AMI [7]. Junjie et al. found that reduced serum miR-30d expression in patients with acute heart failure along with lower hemoglobin and serum sodium levels, may predict an increased morbidity risk over a 1-year period [30]. We revealed that despite the diagnostic value, analyzed miRNAs were not good predictors of cardiovascular events and endpoints during a 1-month follow-up period for STEMI patients.

Alterations of specific miRNA expressions have been linked to severity of cardiovascular diseases in previous reports. Little information exists about the impact of altered miR-23a-3p, miR-30d-5p, and miR-146a-5p expression levels on the severity of STEMI. We found a significant correlation between reduced serum level of miR-23a-3p and increased severity of STEMI along with a higher risk of morbidity. Similar tendencies could be seen in other studies: a downregulation of plasma miR-155 and miR-126-5p had a negative correlation with SYNTAX severity score and reduced miR-126-5p level was significantly associated with multi-vessel disease in CAD patients [31,32]. Liu et al. found that upregulation of plasma miR-134, miR-3135b, and miR-2861 may be associated with the level of coronary artery calcification and expression levels of these miRNA were also significantly altered in patients with obstructive coronary artery disease, verified via angiography [33].

We found that eGFR was decreased for 25.8% of patients with STEMI. Circulating miRNA may be eliminated through kidneys, as Gidlof et al. showed that cardiосpecific miR-1 and miR133a can be identified in urine 12 hours after the onset of STEMI [34]. Significantly lower expression levels of miR-23-3p were detected in sepsis-induced acute kidney injury patients [35]. This urged us to speculate whether the miRNAs investigated in our study were affected by renal function: however, the levels of miR-30d-5p, miR-23a-3p, and miR-146-5p did not significantly differ compared to patients with and without a decrease of eGFR. Finally, little information exists about renal clearance of miRNAs and further studies are needed in this field.

Conclusions

Our results indicated that miR-30d-5p, miR-23a-3p, and miR-146a-5 were downregulated in patients with STEMI compared...
to control group individuals. The high AUC of miR-23a-3p represented the potential diagnostic ability for patients with suspected STEMI. The evaluation of miR-23a-3p expression levels in serum could be useful to assess the severity of STEMI and as a potential diagnostic biomarker of this condition. In addition, miR-23a-3p may provide limited short-term prognostic value for STEMI patients.

**Study limitations**

There were some limitations to our study. This was a single-institution study and tour study had a relatively small sample size, therefore, results need to be interpreted with caution and confirmed by larger multicenter studies. No dynamics of miRNA expression during the early stages of ACS could be evaluated. The results may have been affected by renal insufficiency and the use of medications prior to administration at the CICU and during the hospitalization period before the collection of blood samples.

**References:**

1. Romaine SP, Tomaszewski M, Condorelli G, Samani NJ: MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart, 2015; 101: 921–28
2. Van Schooneveld E, Wildiers H, Vergote I et al: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res, 2015; 17: 21
3. Creemers EE, Tijssen AJ, Pinto YM: Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res, 2012; 110: 483–95
4. Joshi NV, Toor I, Shah ASV et al: Systemic Atherosclerotic Inflammation and extracellular communicators in cardiovascular disease? Circ Res, 2012; 110: 483–95
5. Small EM, Frist RO, Olson EN: MicroRNAs add a new dimension to cardiovascular disease. Circulation, 2010; 121: 1022–32
6. Fichtlscherer S, De Rosa S, Fox H: Circulating microRNAs in patients with coronary artery disease. Circ Res, 2010; 107: 677–84
7. Jia K, Shi P, Han X et al: Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction. Mol Med Rep, 2016; 14: 184–94
8. Wang S, He W, Wang C: MiR-23a regulates the vasculogenesis of coronary artery disease targeting endothelial growth factor receptor. Cardiovasc Ther, 2016; 34: 199–208
9. Wang K, Lin ZQ, Long B et al: Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J Biol Chem, 2017; 282: 589–99
10. Caserta S, Kern F, Cohen J et al: Circulating plasma microRNAs can differentiate human sepsis and systemic inflammatory response syndrome (SIRS). Sci Rep, 2016; 6(1): 28006
11. Huang W, Tian SS, Hang PZ et al: Combination of microRNA-21 and microRNA-146a attenuates cardiac dysfunction and apoptosis during acute myocardial infarction in mice. Mol Ther Nucleic Acids, 2016; 5(3): e296
12. Roffi, M, Patrono, C, Collet JP: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016; 37: 267–315
13. Ibanez B, James S, Agewal S et al: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2018; 39: 119–77
14. Kirschner MB, Kao SC, Edelman JJ et al: Haemolysis during sample preparation alters microRNA content of plasma. PLoS One, 2011; 6(9): e24145
15. McDonald JS, Milosevic D, Reddi HV et al: Analysis of circulating microRNA: Preanalytical and analytical challenges. Clin Chem, 2011; 57: 833–40
16. Schmittgen TD, Livak KJ: Analyzing real time PCR data by the comparative (CT) method. Nat Protoc, 2008; 3: 1310–8
17. Li U, Ren J, Sun Q: The expression of microRNA-23a regulates acute myocardial infarction in patients and in vitro through targeting PTEN. Mol Med Rep, 2018; 17: 6866–72
18. Cheng Y, Zhang R, Yang G et al: Mir-23a inhibition attenuates ischemic/reperfusion-induced myocardial apoptosis by targeting XIAP. Int J Clin Exp Pathol, 2017; 10: 10374–82
19. Peng L, Chun-guang Q, Bei-fang L et al: Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol, 2014; 9: 89
20. Han H, Qu G, Han C et al: MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: A pilot study [published erratum appears in Sci Rep 2015 Apr 11;5(1): 6052]. Sci Rep, 2015; 7(1): 15974
21. Hermenegildo C, Morperon A, Januario T et al: Comparative analysis of miRNA expression in serum and plasma of patients. J Hypertens, 2017; 35: e204
22. Parahuleva MS, Euler G, Mardini A et al: Identification of microRNAs as potential cellular monocytic biomarkers in the early phase of myocardial infarction: A pilot study [published erratum appears in Sci Rep 2018 Apr 11;8(1): 6052]. Sci Rep, 2017; 7(1): 15974
23. Thysgesen K, Alpert JS, White HD et al: Universal definition of myocardial infarction. Eur Heart J, 2007; 28: 2525–38
24. Fliss H, Gattinger D: Apoptosis in ischemic and reperfused rat cardiomyocytes. Circ Res, 1999; 76: 949–56
25. Anversa P, Cheng W, Liu Y et al: Apoptosis and myocardial infarction. Basic Res Cardiol, 1998; 93: 6–12
26. Long B, Tan YZ, Zhang RC, Zhang YH: MiR-23a regulates cardiomyocyte apoptosis by targeting manganese superoxide dismutase. Mol Cells, 2017; 40: 542–49
27. Peng P, Li Z, Liu X: Reduced expression of miR-23a suppresses A2O in TLR-stimulated macrophages. Inflammation, 2011; 34: 199–204
28. Mao J, Lv Z, Zhuang Y: MicroRNA-23a is involved in tumor necrosis factor-α-induced apoptosis in mesenchymal stem cells and myocardial infarction. Exp Mol Pathol, 2014; 97: 23–30
29. Giavarina D, Carta M, Fortunato A et al: Copeptin and high sensitive troponin for a rapid rule out of acute myocardial infarction? Clin Lab, 2011; 57: 725–30
30. Xiao J, Gao R, Bei Y et al: Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem, 2016; 39: 837–46
31. Liu W, Wang S et al: Circulating microRNAs correlated with the level of coronary artery calcification in symptomatic patients. Sci Rep, 2015; 5(1): 16099
32. Li HY, Zhao X, Liu YZ et al: Plasma microRNA-126-5p is associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris. Cell Physiol Biochem, 2016; 39: 837–46
33. Gidlof O, Andersson P, van der Pals J et al: Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology, 2011; 118: 217–26
34. Ge QM, Huang CM, Zhu XY et al: Differentially expressed miRNAs in sepsis-induced acute kidney injury target oxidative stress and mitochondrial dysfunction pathways. PLoS One, 2017; 12(3): e0173292